LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LondonWallet
No Result
View All Result

Morgan Stanley says these are the key energy stocks to buy as oil rises to highest levels of the year

Chaim Potok by Chaim Potok
September 12, 2023
in Investing
Morgan Stanley says these are the key energy stocks to buy as oil rises to highest levels of the year
74
SHARES
1.2k
VIEWS
Share on FacebookShare on Twitter


Morgan Stanley is banking on higher summer oil prices to extend into the fall. A combination of stronger demand and supply cuts pushed crude oil prices higher in the second half of the summer after showing encouraging signs of lower prices. OPEC+, which includes Russia and other nations included in the Organization of the Petroleum Exporting Countries, most recently announced an additional supply cut last month equating to about 1.16 million barrels per day. On Tuesday, oil prices notched their highest level since November 2022, according to FactSet data. Morgan Stanley says the U.S. energy sector is trading at a roughly 50% discount compared to the broader market, when judged by enterprise multiple’s of some firms. Here are Morgan Stanley’s picks to play the trend higher in oil prices. The firm maintains an equal weight rating on oil major Chevron , accompanied by a $198 per share price target. Morgan Stanley’s forecast implies roughly 21% upside from Monday’s $163.76 close. CVX YTD mountain Chevron stock has slipped nearly 9% from the start of the year. Elsewhere, Morgan Stanley rates both ConocoPhillips and Hess at overweight, with price targets of $124 and $158, respectively. That implies about 3% upside for ConocoPhillips and less than 1% for Hess when compared to closing prices from Monday. Among Canadian equities, Morgan Stanley also mentions Cenovus Energy with an overweight rating and a $31 per share price target. The firm’s forecast implies more than 54% upside from Monday’s $20.11 close. CVE YTD mountain Cenovus stock has climbed roughly 4% from the start of 2023. — CNBC’s Michael Bloom contributed to this report.



Source link

You might also like

In a jobs apocalypse, look to ‘AI-proof’ skilled trades, career experts say

Top Wall Street analysts are bullish on these 3 stocks despite ongoing volatility

These momentum trades have fizzled out and are stuck. Where they might go from here

Share30Tweet19
Previous Post

Shoplifting is ‘epidemic’ and ‘incidents haven’t always been responded to by police,’ John Lewis says

Next Post

Canopy Growth’s stock stays hot after big gains, but some cannabis stocks cool

Chaim Potok

Chaim Potok

Recommended For You

In a jobs apocalypse, look to ‘AI-proof’ skilled trades, career experts say
Investing

In a jobs apocalypse, look to ‘AI-proof’ skilled trades, career experts say

March 8, 2026
Top Wall Street analysts are bullish on these 3 stocks despite ongoing volatility
Investing

Top Wall Street analysts are bullish on these 3 stocks despite ongoing volatility

March 8, 2026
These momentum trades have fizzled out and are stuck. Where they might go from here
Investing

These momentum trades have fizzled out and are stuck. Where they might go from here

March 8, 2026
Middle-income homebuyers have ,000 more buying power than a year ago, research finds. It’s still not enough
Investing

Middle-income homebuyers have $30,000 more buying power than a year ago, research finds. It’s still not enough

March 7, 2026
Next Post
Canopy Growth’s stock stays hot after big gains, but some cannabis stocks cool

Canopy Growth’s stock stays hot after big gains, but some cannabis stocks cool

Related News

Humza Yousaf visits popular Highland music festival with family

Humza Yousaf visits popular Highland music festival with family

July 23, 2023
Former Rockspring team reunite to launch Evonite

Former Rockspring team reunite to launch Evonite

May 15, 2024
Gilead Sciences says FDA has approved Veklury in COVID patients with severe kidney disease

Gilead Sciences says FDA has approved Veklury in COVID patients with severe kidney disease

July 14, 2023

Browse by Category

  • Business Finance
  • Crypto
  • Industries
  • Investing
  • Markets
  • Opinion
  • Real Estate
  • UK

London Wallet

Read latest news about finance, business and investing

  • Contact
  • Privacy Policy
  • Terms & Conditions

© 2025 London Wallet - All Rights Reserved!

No Result
View All Result
  • Checkout
  • Contact
  • Home
  • Login/Register
  • My account
  • Privacy Policy
  • Terms and Conditions

© 2025 London Wallet - All Rights Reserved!

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?